

Supplementary data (Appendix S1)

Primary cohort: Renal impairment during induction treatment

During the total induction period, 48 patients (49.5%) treated with CISPEM developed AKD at any time during the induction period compared to 15 patients (29%) treated with CARPEM. The proportion of patients with AKD during CARPEM treatment remained constant around 15% per cycle. In contrast, the occurrence of AKD accumulated with the number of cycles of treatment with CISPEM (20% during cycle 1, 50% during cycle 4) (Figure S1).

Figure S1. Renal function and development of AKD during induction treatment (N = 149) in the primary cohort.

(A) Squares: median eGFR with interquartile range at weekly measurements in patients at risk. Lines: course of renal function during induction pemetrexed combined with cisplatin (solid) and carboplatin (dashed). (B) Columns: weekly percentage of patients at risk who develop acute kidney disease during induction pemetrexed combined with cisplatin (filled) and carboplatin (pattern). Abbreviations: AKD, acute kidney disease; eGFR, estimated glomerular filtration rate; CISPEM, cisplatin combined with pemetrexed; CARPEM, carboplatin combined with pemetrexed; PD, progressive disease; RT, radiotherapy.